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Abstract  
BACKGROUND: The recognition of the complications of obesity in various organs and systems should make 
clinicians and dietitians aware of the importance of early strategies to fight obesity in all age groups.  
AIM: The objective of this study was to evaluate the early effect of using Avena sativa (oat) flour supplement 
compared to a hypocaloric diet in the management of obesity-related metabolic disorders.  
MATERIAL AND METHODS: Snack was prepared from wholemeal wheat flour (100% extraction) and oat flour. 
Chemical analysis of the raw materials and the formulae was carried out. 106 obese women with their mean body 
mass index were 37.73 ± 0.56 kg/m² volunteered for 8 weeks period. They were divided into two groups; group 
(A), consumed hypocaloric diet supplemented by the prepared snack, while group (B) subjects followed the low 
caloric balanced diet. All patients were monitored clinically, anthropometrically, dietary 24 h recall and 
biochemically.  
RESULT: Data demonstrated significantly decreased in the mean levels of the anthropometric parameters. Group 
(A) showed a higher decrease in the waist circumference, WHR, body fat% and SBP; while in group (B) weight, 
BMI, chest circumference and DBP were the most affected parameters. The reduction in the biochemical 
parameters was higher in the group (A). At the baseline, high values of cystatin-C were found in both groups 
which may indicate early renal injury. At the end of the study, a significant reduction of the cystatin concentration 
was observed among both groups (-24.54 & -12.23%). 
CONCLUSION: The healthy effect of the dietary oat supplement on the reduction of central obesity, percentage 
body fat and different metabolic disorders criteria was confirmed than with hypocaloric diet. 
 
 
 
 
 
Introduction 
 
James, (2008) reported that obesity is a 
standout amongst the most genuine general medical 
issues in the 21st century [1]. Eighty-five per cent of 
Egyptian women are overweight with 48 per cent of 
that rate enduring obesity, as indicated by Egypt 
Demographic and Health Survey (EDHS 2014) 
reported by Egypt’s health minister, the per cent of 
obese women was twice that of men [2].  
Fat accumulation, especially in the abdominal 
region, is associated with metabolic disturbances such 
as dyslipidemia, hypertension, insulin resistance, 
cardiovascular complications and non-alcoholic fatty 
liver disease. Recent studies demonstrated that 
obesity independently of diabetes might have a role in 
the development of kidney disease (obesity-related 
nephropathy) and may lead to end-stage renal 
disease. The prevalence of obesity runs in parallel 
with the prevalence of renal failure. The intrarenal 
changes associated with the cardiometabolic 
syndrome result in elevated glomerular filtration rate, 
impaired pressure natriuresis, endothelial dysfunction 
related to changes in nitric oxide and, hence, impaired 
renal autoregulation and enhanced chronic 
inflammation [3] [4]. 
Cystatin C is a protein of 120 amino acids 
delivered in every nucleated cell of the human body 
and is found in practically all tissues and body liquids. 
It has a low atomic weight, so it is unreservedly 
filtered by the glomerulus and reabsorbed and 
debased by the proximal tubules. It is an endogenous 
filtration marker that is being considered as a potential 
substitution of serum creatinine in the evaluation of 
renal capacity, predominantly for the identification of 
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little changes in the glomerular filtration rate, since it is 
asserted to be free of age, sex, skeletal bulk and 
protein consumption [5]. Sledzinsk and others 
demonstrated that human obesity is associated with 
an abnormality in cystatin-C value, and that fat tissue 
elevated serum cystatin-C in obese subjects [6].  
Oat (Avena sativa) has a nutritional profile 
and multifunctional attributes. It is considered a richer 
source of dietary fibre particularly beta-glucan, 
minerals and different elements. Wholegrain oat-
based breakfast grains considered as prebiotics and 
have low glycemic index (GI) [7].  
The present study aimed to evaluate the early 
effect of using Avena sativa (oat) flour supplement 
compared to a hypocaloric diet in the management of 
obesity-related metabolic disorders and the risk of 
renal disease.  
 
 
Materials and Methods 
 
The snack was prepared from wholemeal 
wheat flour (WMWF) (100% extraction) and oat flour 
(OF) added in equal amounts (at the level of 50%). 
The flour was mixed with the other ingredients 
(Skimmed milk, corn oil, baking powder and vanilla) 
and a suitable amount of water was added. These 
formulae were baked at 180°C for about 15 minutes 
[8] (Figure 1). WMWF 100% extractions had more 
beneficial health effect than Wheat flour (WF) 72% 
extraction [9]. 
Table 1: Composition of the supplement (g/100g dry weight) 
Items Snack 
Oat Flour  38.7 
Whole Meal Wheat Flour 100% extraction 38.7 
Vanilla 0.5 
Skimmed milk 10.8 
Baking powder 0.5 
Corn oil 10.8 
 
One hundred and six obese females with BMI 
more than 30 kg/m² were included in this study with 
their age ranged from 39 to 57 years old, and their 
mean body mass index (BMI) was 37.73 ± 0.56 kg/m². 
They were all enrolled in a program for losing weight 
in the Nutrition Department, National Research 
Centre. The participants were informed about the 
purpose of the study and their permission in the form 
of written consent was obtained. The protocol was 
approved by the "Ethical Committee" of the "National 
Research Centre". All participants have followed a low 
caloric balanced regimen (1000-1200 KCal/day) for 
eight weeks. They were divided into two groups, sixty-
six patients (group A) consumed the snack, two with 
breakfast and one with dinner (each weighed 20 g), 
and the rest of the sample (40) group (B) followed a 
low caloric balanced regimen without supplement for 
eight weeks. All the subjects were examined at 
baseline, and the end of the study with weekly follow 
up. 
  
Figure 1: Prepared snack 
 
Exclusion criteria: Obese patients on 
pharmacological treatment, known to have renal 
failure or thyroid dysfunction.  
Body weight and height (subjects were 
standing with minimum clothing and no shoes to the 
nearest 0.01 centimetre). Minimal waist circumference 
(MWC) was measured in centimetre using non-
extendable tape during minimal normal respiration 
and hip circumference. The body mass index (BMI) 
was Calculated, where BMI = weight in kg/square 
height in meters [10] (Jelliffe, 1966). Body fat (BF) as 
a per cent of body weight, body muscle mass and the 
basal metabolic rate was measured using Geratherm 
Body Fitness (B-5010), German.  
Blood pressure was measured by cuff 
sphygmomanometer while the subjects sat quietly on 
a chair, and the mean of three readings was taken.  
Data on dietary intake before the intervention 
were reported using the 24 hours dietary intake recall. 
All food items and portions were recorded in details. 
Total nutrients intake was calculated using 
Nutrisurvey 2007.  
Blood samples were obtained on the day of 
clinical examination after an overnight fast. Fasting 
blood glucose (FBG) was determined in fresh samples 
using the glucose oxidase method [11]. Serum total 
cholesterol (TC), High-density lipoprotein cholesterol 
(HDL-C) and triglycerides (TG) were done using; 
cholesterol proceed No 1010, StanBio Liquicolor [12]. 
HDL-C proceed No 0599 StanBio Liquicolor [13], and 
triglycerides proceed No 2100, (Enzymatic method) 
[14] respectively. Low density lipoprotein- cholesterol 
(LDL-C) was calculated according to the Friedewald 
equation [15]. Fasting C-peptide level was measured 
by ELISA method [16] (Monobind Inc. Lake Forest, 
CA 92630, USA). According to Li et al., [17] (2004), 
insulin resistance was expressed by modified 
homeostasis model assessment-insulin resistance 
(modified HOMA-IR = 1.5 + FBG (mg/dl) × fasting C-
peptide (nanograms per milliliter)/2,800), in which 
insulin was replaced by C-peptide so as to be applied 
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on diabetic patients using exogenous insulin. 
Aspartate aminotransferase (AST/GOT) and alanine 
aminotransferase (ALT/GPT) were measured by 
colourimetric method [18]. DeRitis ratio was calculated 
as AST/ALT. Serum Cystatin-C was determined using 
Human Cystatin-C ELISA, Lot E12-076, BioVendor 
Research and Diagnostic Product CZECH REPUBLIC 
[19].  
All values were expressed as mean value ± 
SE. Two-tailed student t-test was used to compare 
between data in the same group and between groups. 
P values < 0.05 were considered statistically 
significant. SPSS window software version 17.0 
(SPSS Inc. Chicago, IL, USA, 2008) was used. 
Changes in different data were expressed as % 
change from baseline. 
 
 
Results 
 
Table 2 summarised the average of protein, 
fat and crude fibre of the raw materials and the oat 
prepared snack, in addition to some mineral contents 
of the product. 
Table 2: Chemical composition of raw materials and snack 
(mean ± SE) 
Fibre (%) Fat (%) Protein (%) Samples 
1.75 ± 0.001 2.5 ± 0.01 13.5 ± 0.10 WMWF 
4.82 ± 0.002 5.0 ± 0.05 16.8 ± 0.17 Oat flour 
3.50 ± 0.007 12.15 ± 0.06 16.32 ± 0.12 Snack 
Na % Zn% K % Minerals 
302.34 5.34 320.96 Snack 
WMWF: Whole Meal Wheat Flour (100% extraction); Snack prepared by 50% 
WMWF+50% Oat Flour. 
 
Table 3 showed a comparison between the 
different macronutrients and micronutrients and the 
per cent caloric distribution of the diet of the whole 
sample. The data showed the balanced and healthy 
distribution of the macronutrients in the two regimens 
compared to the habitual diet of the patients. 
Table 3: Daily intake of calories, macronutrient (as a % of 
calories), Mean values and % of the recommended dietary 
allowance (RDAs) of some micronutrient intake of three types 
of diet  
Diet with 
Supplement 
 
Low Caloric 
Regimen 
Habitual Diet 
 
Macronutrient Intake 
1229.87 1239.91 2802.61 Energy (Kcal) 
25.44% 21.48% 13.99% Protein (% cal. supply ) 
28.96% 29.94% 40.92% Fat (% cal. supply) 
45.60% 48.58% 45.09% Carbohydrate (% cal. supply) 
Mean value 
%RDAs 
Micronutrient intake 
(RDAs) 
774.21 
96.78 
765.24 
95.66 
567.24 
70.91 
Vit. A (µg) 
(800) 
3.23 
64.60 
3.21 
64.20 
1.97 
39.40 
Vit. D (µg) 
(5) 
1669.95 
83.49 
1633.51 
81.68 
929.93 
46.49 
Potassium (mg) 
(2000) 
920.32 
92.03 
891.46 
89.15 
731.63 
73.16 
Calcium (mg) 
(1000) 
11.83 
78.87 
11.12 
74.13 
6.35 
42.33 
Iron (mg) 
(15) 
10.98 
91.50 
10.45 
87.08 
6.27 
52.25 
Zinc (mg) 
(12) 
Table 4 showed the mean ± SE of age, 
anthropometric, blood pressure measurements of the 
two groups at the start and the end of the study. All 
the anthropometric measurements except body 
muscle mass of the two groups decreased 
significantly at p < 0.05-0.01 by the end of the study. 
Comparing the % changes between the two groups; 
group (A) showed more % reduction of waist 
circumference, WHR, body fat % and SBP, while in 
the group (B) the higher per cent of reduction was 
observed in weight, BMI, chest circumference and the 
DBP. 
Table 4: Mean ± SE of anthropometric parameters and blood 
pressure of obese women at the baseline and the end of the 
study 
 Groups A (n = 66) Groups B (n = 40) 
Parameters Baseline Last % 
changes 
Baseline last % 
changes 
Age (year) 50.18±0.64   50.11±0.80   
Height (cm) 155.5±0.78   155.00±0.76   
Weight (Kg) 91.39±1.33 87.63±1.40
**a
 -4.11 90.10±1.04 86.09±1.02
**b 
-4.45
**c
 
BMI 
(Kg/m
2
) 
37.88±0.56 37.04±0.58
**a
 -2.21 37.59±0.46 36.27±0.47
**b
 -3.51
**c
 
Body fat 
(%) 
47.83±0.65 46.37±0.73
**a
 -3.05 48.83±0.84 47.94±0.84
**b
 -1.82
**c
 
Body 
muscle (kg) 
42.45±0.46 42.43±0.40 -0.04 42.15±0.36 41.98±0.37 -0.40 
Chest (cm) 96.05±0.67 94.46±0.57
**a
 -1.66 98.18±0.55 95.14±0.53
**b 
-3.06
**c
 
Waist (cm) 95.32±0.76 92.33±0.99
**a
 -3.14 95.00±1.19 93.62±1.03
**b 
-1.45
**c
 
WHR 0.79±0.01 0.77±0.00
**a
 -2.53 0.81±0.01 0.80±0.11
**b
 -1.23
**c
 
SBP 
(mmHg) 
132.67±1.37 116.67±1.77
**a
 -12.06 126.88±2.80 117.64±1.79
**b
 -7.85
**c
 
DBP 
(mmHg) 
79.33±0.82 76.67±1.18
*a
 -3.35 82.22±1.55 78.33±1.43
**b
 -4.97
*c
 
BMI: body mass index, WHR: waist-hip ratio, SBP: systolic blood pressure, DBP: diastolic 
blood pressure *P<0.05 **P<0.01, a: Baseline vs. last visit of group A; b: Baseline vs. last 
visit of group B; c: % changes group A vs. group B. 
 
Table 5 showed the mean± SE of the 
biochemical parameters of the two groups at the two 
visits. The level of HDL-C increased significantly, 
while the FBG concentration, other lipid parameters, 
liver enzymes and cystatin-C levels showed a 
significant reduction in the mean concentrations of 
both groups with more effect on group A except for 
AST serum level. The comparison between the two 
groups regarding the mean per cent changes 
approached significance on all parameters. 
Table 5: Mean ± SE of the Obesity-related metabolic disorders 
of obese women at the baseline and the end of the study 
 Groups A (n = 66) Groups B (n = 40) 
Parameters Baseline last % 
changes 
Baseline last % 
changes 
FBG (mg/dl) 95.76±2.45 79.67±1.50
**a
 -16.80 84.83±1.32 83.35±1’12 -1.74
**c 
TC (mg/dl) 232.94±6.29 184.02±4.41
**a 
-21.00 218.76±6.66 205.68±7.24
**b
 -5.99
**c
 
LDL-C (mg/dl) 151.29±6.41 97.09±4.77
**a
 -35.89 151.19±4.82
 
126.89±4.80
**b 
-16.07
**c
 
HDL-C (mg/dl)  49.71±1.20 62.19±1.44
**a 
+25.11 49.23±1.61 53.39±2.61
**b
 +8.45
**c
 
Non HDL-C 
(mg/dl) 
183.23±6.82 121.83±4.99
**a 
-33.51 159.52±7.59
 
152.28±8.62
**b 
-4.54
**c
 
Risk factor 
((TC/ HDL) 
4.99±0.23 3.12±0.13
**a
 -37.47 4.90±0.16 3.99±0.14
**b 
-29.35
**c
 
TG (mg/dl) 159.68±6.00 123.70±3.56
**a
 -22.53 125.15±6.03 110.93±4.42
**b
 -11.36
**c
 
AST (IU/L) 32.86±0.90 29.27±0.95
**a
 -10.93 28.97±0.90 25.19±0.60
**b
 -13.05
*c
 
ALT (IU/L) 50.85±0.79 38.28±0.79
**a
 -24.72 51.72±0.48 49.80±0.96
**b
 -3.71
**c
 
DeRitis ratio 0.65± 0.01 0.78±0.02
**a
 +20 0.56 ±0.02 0.62±0.03 +10.71
**c
 
C peptide 
(ng/ml) 
4.44±0.38 2.37±0.25**a -46.62 5.22±0.28 3.40±0.18 -34.87
**c
 
M. HOMA-IR 1.67±0.01 1.58±0.01
**a
 -5.39 1.66±0.01 1.58±0.01 -4.94
*c
 
Cystatin C 
(ng/ml) 
965.25±38.23 728.37±24.11
**a 
-24.54 957.44±45.99 840.37 ±42.12 -12.23
**c
 
FBG: fasting blood glucose; AST: aspartate transaminase; ALT: alanine transaminase; M.HOMA-IR: 
modified homeostatic model assessment of insulin resistance *P<0.05 **P<0.01; a: Baseline vs. last visit of 
group A; b: Baseline vs. last visit of group B; c: % changes group A vs. group B. 
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Discussion 
 
Obesity is a state of low-grade inflammation 
and pro-oxidation which lead to vascular dysfunction 
and altered the metabolic states resulting in an 
alteration in the liver and kidney functions. The 
baseline information of this study uncovered that all 
volunteers had elevated levels of all the 
anthropometric measurements, lipid profile 
parameters and the cystatin-C concentration over the 
recorded reference values that indicated metabolic 
disarranges. At the beginning of the investigation, the 
diabetic members had a normal value of the FBG, as 
they were under medical treatment. Nonetheless, 
serum C-peptide as a marker of the functional- 
pancreatic cell mass, showed mild rise (> 3.75 ng/ml). 
Rosselli et al., (2013) expressed that C-peptide 
expects a role in early atherogenesis in diabetic 
patients; also it might be considered a marker to 
cardiovascular diseases risks in patients without 
diabetes [20]. 
 Data in this study demonstrated the healthy 
beneficial effect of the supplement consumed by the 
patients on the central obesity measurements (waist 
circumference and WHR) and the blood pressure 
values. The higher per cent decrease was found in the 
systolic blood pressure percentage where it was -
12.06 & -7.85% group (A) and group (B) respectively, 
that followed by the decrease in the body fat 
percentage values (-3.05 & -1.82%) and WHR (-2.53 
& -1.23%). The body weight and BMI were 
significantly decreased more in the low caloric diet 
group (-4.11 & -4.45%) and (-2.21 & -3.51%) 
respectively. Furthermore, the improvement of the 
biochemical parameters was high in its value when 
compared to the supplements’ effect on the 
anthropometric measurements. The mean level of the 
FBG decreased significantly (-16.8 & -1.74%) in both 
groups, but was much more in the group (A). All the 
biochemical parameters improved significantly in both 
groups, especially in group A.  
Interest in β-glucan increased due to its 
bioactive and functional properties with no adverse 
effects following consumption of a diet rich in it as 
barley, oat or their extracts [21]. The health benefits of 
these foods arise from their high fibers content which 
ranges from 9.9-14.9 g for each 100 g serving and 
lipid-lowering effect of β-glucan, either by bile acid 
binding, delay in the absorption and/or digestion of fat, 
filling full, suppress appetite and finally β-glucan 
depress oxidative stress associated with inflammatory 
state caused by obesity [22]. 
Oats additionally contain more lipids (5-9%) 
than other grain edits and are rich in unsaturated fats, 
including the basic unsaturated fat linoleic acid. Oats 
contain antioxidant, called avenanthramides, and also 
the vitamin E-like compound, tocotrienols and 
tocopherols (Wursch and Pi-Sunyer, 1997) [23] [24] 
[25]. 
Body muscle mass decreased numerically in 
both groups; this result focuses the importance of 
consuming supplement enriched on amino acid as soy 
products, the preservation of body muscle mass is a 
must in any overweight, losing program [26].  
Correlation between obesity and renal 
impairment has been demonstrated by several types 
of research. The gradual expansion of renal 
tubulointerstitial fibrosis by fibrous tissue destroys the 
normal structure of the kidney. More, the local release 
of inflammatory substances and active biological 
factors result in renal impairment. Other theory states 
that obesity leads to endothelial dysfunction and 
thickness of the intima-media resulting in vascular 
damage and leaking of albumin. Obesity, when 
present since childhood, is associated with a lower 
glomerular filtration rate even before the appearance 
of other comorbidities as diabetes and hypertension 
[27] [28] [29] [30].  
Clinical markers used to reflect renal damage 
incorporate albuminuria and the assessed glomerular 
filtration rate (GFR). Given the same GFR level, urine 
albumin may be a superior marker to foresee the 
progression of chronic kidney disease (CKD) and the 
future of cardiovascular diseases (CVDs). Serum 
cystatin-C is rising as another biomarker for early 
identification of renal damage related to obesity, MetS 
and cardiovascular disease [31] [32] [33]. Weight 
control, strict control of blood pressure, glucose and 
lipid levels decrease renal damage and even the 
ensuing CVD [34].  
In this study, high values of cystatin-C were 
detected in both groups at the beginning of this study 
which may indicate early renal injury. After the end of 
the study, a significant reduction of the cystatin-C 
concentration was observed among both groups more 
in the oat supplement group (-24.54 & -12.23%). 
Animal examinations revealed that oat consumption 
affects kidney function. In any case, the impacts of oat 
utilisation have not been completely evaluated in 
humans. However, Rouhani et al., (2016) conducted a 
study that investigated fifty-two patients with CKD; the 
authors reported that admission of oats might 
beneficially affect both serum albumin and potassium 
[35].  
The results of this study showed the high 
value of the ALT enzyme and the De Ritis ratio was (< 
1.0) at the beginning of the study in both groups, 
denoting the presence of early nonalcoholic fatty liver 
disease (NAFLD). At the end of the study, a significant 
reduction in the levels of both liver enzymes was 
detected, and the De Ritis ratio was improved in both 
groups. Improvement of insulin resistance with oat 
supplement or dietary interventions constitutes an 
essential step in the treatment of NAFLD. Excessive 
triglyceride accumulation in the liver in the absence of 
alcohol consumption results in a disorder known as 
NAFLD. Insulin sensitisers and antioxidant drugs hold 
promise for the management of NAFLD [36] [37].  
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In conclusion, whole wheat ﬂour and oat flour 
snack prepared supplement have higher nutritive 
values. Oat is an essential food component used in 
the modulation of obesity-related metabolic disorders 
and renal impairment. 
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Signed written informed consents was a must to 
participate in the research project after they had been 
given a full explanation of the study. 
 
 
References 
 
1. James WP. WHO recognition of the global obesity epidemic. Int 
J Obes (Lond). 2008; 32(Suppl 7): S120-6. 
https://doi.org/10.1038/ijo.2008.247 PMid:19136980  
2. Central Agency for Public Mobilization and Statistics. Statistical 
Yearbook 2014. Cairo: [Arab Republic of Egypt], 2014.  
3. Praga M, Morales E. The fatty kidney: obesity and renal disease. 
Nephron. 2017; 136(4):273-6. https://doi.org/10.1159/000447674 
PMid:27414023  
 
4. Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney 
disease, and fatty liver disease: the roles of fetuin-A, adiponectin, 
and AMPK. J Am Soc Nephrol. 2010; 21:406-412. 
https://doi.org/10.1681/ASN.2009080820 PMid:20150538 
PMCid:PMC4473254 
 
5. Ortiz F, Harmoinen A, Paavonen T, Koskinen P, Gronhagen-
Riska C, Honkanen E. Is Cystatin C more sensitive than creatinine 
in detecting early chronic allograft nephropathy? Clin Nephrol. 
2008; 70(1):18-25. https://doi.org/10.5414/CNP70018 
PMid:18793544  
 
6. Śledziński T, Proczko-Markuszewska M, Kaska Ł, Stefaniak T, 
Świerczyński J. Serum cystatin C in relation to fat mass loss after 
bariatric surgery. Polish Journal of Surgery. 2012; 84(4):202-7. 
https://doi.org/10.2478/v10035-012-0033-0 PMid:22698658  
 
7. Connolly ML, Tuohy KM, Lovegrove JA. Wholegrain oat-based 
cereals haveprebiotic potential and low glycaemic index. Br J Nutr. 
2012; 108:2198-206. https://doi.org/10.1017/S0007114512000281 
PMid:22360862  
 
8. AOAC. Official Methods of Analysis of the Association of Official 
Analytical Chemists, 17th ed, Association of Official Analytical 
Chemists, Arlington, Vitginia, USA, 2000. 
 
9. El-Shebini SM, Moaty MIA, Fouad S, and Tapozad ST. Serum 
Retinol Binding Protein-4 to Probe Insulin Resistance and 
Atherogenic Dyslipidemia in Metabolic Syndrome Patients 
Following a Diet Therapy. Research Journal of Pharmaceutical, 
Biological and Chemical Sciences. RJPBCS. 2016; 7(1):1903-
1909. 
 
10. Jelliffe DB, The assessment of the nutritional status of the 
community. World Health Organization, Geneva Monograph. 1966; 
35: 63-69. 
 
11. Barham D, Trinder P. An improved colour reagent for 
determination of blood glucose by oxidase system. Analyst. 1972; 
97:142-145. https://doi.org/10.1039/an9729700142 PMid:5037807  
 
12. Allain CC, Poon LS, Chan CS, Richmond WF, Fu PC. 
 
Enzymatic determination of total serum cholesterol. Clinical 
chemistry. 1974; 20(4):470-5. PMid:4818200  
13. Wornick DF, Albers JJ. A comprehensive evaluation of the 
heparin-manganese precipitation procedure for estimating high 
density lipoprotein cholesterol. J Lipid Res.1978; 19:65-76. 
 
14. Seidel J, Klos S, Ziegenhorn T. AACC Meeting Abstract 34. 
Clin Chem. 1993; 39:1127.  
15. Friedewald WI, Levy RI and Fredrickson DS. Estimation of the 
concentration of low density lipoprotein cholesterol in plasma 
without use of preparative ultracentrifuge. Clin Chem. 1972; 
18:499-502. PMid:4337382  
 
16. Bonser AM, Garcia-Webb P, Harrison LC. C-peptide 
measurement: methods and clinical utility. CRC Critical Reviews in 
Clinical Laboratory Sciences. 1984; 19(4):297-352. 
https://doi.org/10.3109/10408368409165766 PMid:6373142  
 
17. Li X, Zhou ZG, Qi HY, Chen XY, Huang G. Replacement of 
insulin by fasting C-peptide in modified homeostasis model 
assessment to evaluate insulin resistance and islet beta cell 
function. Zhong nan da xue xue bao. Yi xue ban = Journal of 
Central South University. Medical sciences. 2004; 29(4):419-23. 
 
18. Huang XJ, Choi YK, Im HS, Yarimaga O, Yoon E, Kim HS. 
Aspartate aminotransferase (AST/GOT) and alanine 
aminotransferase (ALT/GPT) detection techniques. Sensors. 2006; 
6(7):756-82. https://doi.org/10.3390/s6070756 
 
19. Hossain M A, Emara M, El moselhi H, Shoker A: Comparing 
measures of Cystatin C in human sera by three methods. Am J 
Nephrology. 2009; 29(5):381–391. 
https://doi.org/10.1159/000168486 PMid:18974639  
 
20. Rosselli MS, Lotersztain F, Vizzuttif U, Arena M, and Marra F. 
The metabolic syndrome and chronic liver disease. Curr Pharm 
Des. 2013. 
 
21. Tosh SM, Shea Miller S. Health Effects of β-Glucans Found in 
Cereals. 2016, Encyclopedia of Food Grains (Second Edition), 
2016; 2:236–240. 
 
22. El Khoury D, Cuda C, Luhovyy BL, and Anderson G H. Beta 
Glucan: Health Benefits in Obesity and Metabolic Syndrome. J Nutr 
Metab. 2012; 851362. https://doi.org/10.1155/2012/851362 
 
23. Würsch P, Pi-Sunyer FX. The role of viscous soluble fiber in 
the metabolic control of diabetes: a review with special emphasis 
on cereals rich in β-glucan. Diabetes Care. 1997; 20(11):1774-80. 
https://doi.org/10.2337/diacare.20.11.1774 PMid:9353622  
 
24. Hager AS, Ryan LA, Schwab C, Gänzle MG, O'Doherty JV, 
Arendt EK. Influence of the soluble fibres inulin and oat β-glucan 
on quality of dough and bread. European Food Research and 
Technology. 2011; 232(3):405-13. https://doi.org/10.1007/s00217-
010-1409-1 
 
25. Sadiq-Butt M, Tahir-Nadeem M, Khan MK, Shabir R, Butt MS. 
Oat: unique among the cereals. Eur J Nutr. 2008; 47:68-79. 
https://doi.org/10.1007/s00394-008-0698-7 PMid:18301937  
 
26. Fouad S, El Shebini S M, Moaty M I, Hassan N H and 
Tapozada S T. Effect of Soya Beans Bread Fortified with Turmeric 
or Ginger on Diabesity. Der Pharma Chemica. 2016; 8(18):398-
405. 
 
27. Friedman AN, Wahed AS, Wang J, et al. Effect of bariatric 
surgery on CKD risk. J Am Soc Nephrol. 2018. 
https://doi.org/10.1681/ASN.2017060707 PMid:29335242  
 
28. Chen HM, Shen WW, Ge YC, Zhang YD, Xie HL, Liu ZH. The 
relationship between obesity and diabetic nephropathy in China. 
BMC nephrology. 2013; 14(1):69. https://doi.org/10.1186/1471-
2369-14-69 PMid:23521842 PMCid:PMC3614546 
 
29. Abitbol C & Rodríguez M. Obesity-related nephropathy in 
children. Pediatric Health. 2009; 3(2):141-153. 
https://doi.org/10.2217/phe.09.11 
 
30. V Mathew A, Okada S, Sharma K. Obesity related kidney 
disease. Current diabetes reviews. 2011; 7(1):41-9. 
https://doi.org/10.2174/157339911794273928 
 
31. Shardlow A, McIntyre NJ, Fraser SD, Roderick P, Raftery J, 
Fluck RJ, McIntyre CW, Taal MW. The clinical utility and cost  
 El Shebini et al. Obesity Related Metabolic Disorders and Risk of Renal Disease 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2018 Aug 20; 6(8):1376-1381.                                                                                                                                                  1381 
 
impact of cystatin C measurement in the diagnosis and 
management of chronic kidney disease: A primary care cohort 
study. PLoS medicine. 2017; 14(10):e1002400. 
https://doi.org/10.1371/journal.pmed.1002400 PMid:29016597 
PMCid:PMC5634538 
32. Ferguson TW, Komenda P, Tangri N. Cystatin C as a 
biomarker for estimating glomerular filtration rate. Curr Opin 
Nephrol Hypertens. 2015; 24(3):295–300. 
https://doi.org/10.1097/MNH.0000000000000115 PMid:26066476  
 
33. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, 
Greene T, et al. Estimating glomerular filtration rate from serum 
creatinine and cystatin C. N Engl J Med. 2012; 367(1):20–9. 
https://doi.org/10.1056/NEJMoa1114248 PMid:22762315 
PMCid:PMC4398023 
 
34. Iglesias P, Díez JJ. Adipose tissue in renal disease: clinical 
significance and prognostic implications. Nephrology Dialysis 
Transplantation. 2010; 25(7):2066-77. 
https://doi.org/10.1093/ndt/gfq246 PMid:20466661  
 
35. Rouhani MH, Najafabadi MM, Surkan PJ, Esmaillzadeh A, Feizi 
A, Azadbakht L. The impact of oat (Avena sativa) consumption on  
biomarkers of renal function in patients with chronic kidney 
disease: A parallel randomized clinical trial. Clin Nutr. 2016; 
(16)31339-5. 
36. Mellinger JL, Pencina KM, Massaro JM, Hoffmann U, Seshadri 
S, Fox CS, O'Donnell CJ, Speliotes EK. Hepatic steatosis and 
cardiovascular disease outcomes: an analysis of the Framingham 
Heart Study. Journal of hepatology. 2015 Aug 1; 63(2):470-6. 
https://doi.org/10.1016/j.jhep.2015.02.045 PMid:25776891 
PMCid:PMC5282653 
 
37. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi 
K, Charlton M, Sanyal AJ. The diagnosis and management of non-
alcoholic fatty liver disease: practice guideline by the American 
Gastroenterological Association, American Association for the 
Study of Liver Diseases, and American College of 
Gastroenterology. Gastroenterology. 2012 Jun 1; 142(7):1592-609. 
https://doi.org/10.1053/j.gastro.2012.04.001 PMid:22656328  
 
 
